Sino Biopharmaceutical

Explore the latest insights on Sino Biopharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Sino Biopharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Sino Biopharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Sino Biopharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms
CompanyDeals

Bio-Link Capital Completes Strategic Investment in TYK Medicines – Doubling Down on Bispecific, Trispecific and ADC Antibody Platforms

Bio-Link Capital announced the completion of a strategic investment in TYK Medicines (HKG: 2410), a macromolecule innovative drug company focused on the development of next‑generation antibody therapeutics, including bispecific antibodies,…

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Sino Biopharmaceutical Terminates IPO Pre-Listing Process for STAR Board

CompanyDeals

F-Star Therapeutics and Sino Biopharmaceutical Seek CFIUS Approval with Extended Deadline

CompanyDrug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

CompanyDeals

Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China

CompanyDeals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

CompanyDeals

F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition

CompanyDeals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

CompanyDrug

Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review

Show More